Summary
ADVENTRX Pharmaceuticals, Inc. (Adventrx) is a biopharmaceutical company, involved in the acquisition, development and commercialization of pharmaceuticals in the areas of hematology and oncology. The company operates its business in a single reportable segment which is development of proprietary drug candidates. The product pipeline of the company includes ANX-188 which is an aqueous solution of purified form of poloxamer 188 for the treatment of sickle cell disease indications; ANX-154 which is an emulsion formulation of docetaxel to treat solid tumors; and Exelbine which is a novel emulsion formulation of the chemotherapy drug vinorelbine. The company operates through its two subsidiaries, namely, SD Pharmaceuticals, Inc., SynthRx, Inc. and ADVENTRX (Europe) Ltd. The company is headquartered in San Diego, California, the US
The company aims at the successful discovery, development and marketing of its proprietary product candidates focused on huge-demand market of oncology and hematology. This intent can be reflected from the recent review discussions with the US Food and Drug Development (FDA) for optimal development programs with respect to its product candidates ANX-514 and ANX-188 as well as the public offering of its common shares in order to finance the clinical programs.
Adventrx Pharmaceuticals, Inc. Key Recent Developments
Aug 14, 2012: Adventrx Pharma Appoints Santosh Vetticaden As Chief Medical Officer
Aug 06, 2012: Adventrx Pharma Reports Q2 2012 Results
May 07, 2012: Adventrx Pharma Reports Q1 2012 Results
Mar 07, 2012: ADVENTRX Pharma Reports Q4 2011 Results
Nov 07, 2011: ADVENTRX Pharma Reports Q3 2011 Results
This comprehensive SWOT profile of Adventrx Pharmaceuticals, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Note: Some sections may be missing if data is unavailable for the company.
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Pharmaceutical Industry in the United States
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Adventrx Pharmaceuticals, Inc. - Key Facts 5
Adventrx Pharmaceuticals, Inc. - Key Employees 6
Adventrx Pharmaceuticals, Inc. - Major Products and Services 7
Adventrx Pharmaceuticals, Inc. - Pharmaceutical Pipeline Products Data 8
Adventrx Pharmaceuticals, Inc., Pipeline Products by Therapy Area 8
Adventrx Pharmaceuticals, Inc., Pipeline Products by Development Phase 9
Adventrx Pharmaceuticals, Inc. - History 11
Adventrx Pharmaceuticals, Inc. - Company Statement 13
Adventrx Pharmaceuticals, Inc. - Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 16
Adventrx Pharmaceuticals, Inc. - Business Description 16
Adventrx Pharmaceuticals, Inc. - Corporate Strategy 17
Adventrx Pharmaceuticals, Inc. - SWOT Analysis 18
SWOT Analysis - Overview 18
Adventrx Pharmaceuticals, Inc. - Strengths 18
Strength - Sturdy R&D Activities 18
Strength - Strong Patent Portfolio 18
Strength - Strong Liquidity Position 18
Adventrx Pharmaceuticals, Inc. - Weaknesses 18
Weakness - Lack of Product Based Revenues 18
Adventrx Pharmaceuticals, Inc. - Opportunities 19
Opportunity - Market Opportunities - Oncology 19
Opportunity - Changing Demographies 19
Opportunity - Inorganic Growth Strategies 19
Adventrx Pharmaceuticals, Inc. - Threats 20
Threat - Stringent Government Regulations 20
Threat - Competitive Pressures 20
Threat - Uncertain R&D Outcomes 20
Threat - Dependence on Third Party Manufacturing 20
Adventrx Pharmaceuticals, Inc. - Key Competitors 21
Section 3 – Company Financial Ratios 22
Financial Ratios - Capital Market Ratios 22
Financial Ratios - Annual Ratios 22
Performance Chart 23
Financial Performance 23
Financial Ratios - Interim Ratios 24
Financial Ratios - Ratio Charts 25
Section 4 – Company’s Lifesciences Financial Deals and Alliances 26
Adventrx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 26
Adventrx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 27
Adventrx Pharmaceuticals, Inc., Recent Deals Summary 28
Section 5 – Company’s Recent Developments 29
Adventrx Pharmaceuticals, Inc., Recent Developments 29
Aug 14, 2012: Adventrx Pharma Appoints Santosh Vetticaden As Chief Medical Officer 29
Aug 06, 2012: Adventrx Pharma Reports Q2 2012 Results 29
May 07, 2012: Adventrx Pharma Reports Q1 2012 Results 30
Mar 07, 2012: ADVENTRX Pharma Reports Q4 2011 Results 30
Nov 07, 2011: ADVENTRX Pharma Reports Q3 2011 Results 30
Oct 19, 2011: ADVENTRX Pharmaceuticals To Present At 10TH Annual BIO Investor Forum 31
Aug 08, 2011: ADVENTRX Pharmaceuticals Reports Q2 2011 Results 31
Jul 25, 2011: ADVENTRX Appoints Gregory Gorgas As Senior Vice President, Commercial 31
May 09, 2011: ADVENTRX Pharmaceuticals Reports Net Loss Of $3m For Q1 2011 31
Mar 10, 2011: ADVENTRX Reports Net Loss Of $2.3m For Q4 2010 32
Section 6 – Appendix 33
Methodology 33
Ratio Definitions 33
About GlobalData 37
Contact Us 37
Disclaimer 37
List of Tables
Adventrx Pharmaceuticals, Inc., Key Facts 5
Adventrx Pharmaceuticals, Inc., Key Employees 6
Adventrx Pharmaceuticals, Inc., Major Products and Services 7
Adventrx Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 8
Adventrx Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 9
Adventrx Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 10
Adventrx Pharmaceuticals, Inc., History 11
Adventrx Pharmaceuticals, Inc., Subsidiaries 15
Adventrx Pharmaceuticals, Inc., Key Competitors 21
Adventrx Pharmaceuticals, Inc., Ratios based on current share price 22
Adventrx Pharmaceuticals, Inc., Annual Ratios 22
Adventrx Pharmaceuticals, Inc., Interim Ratios 24
Adventrx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 26
Adventrx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2006 to YTD 2012 27
Adventrx Pharmaceuticals, Inc., Recent Deals Summary 28
Currency Codes 33
Capital Market Ratios 33
Equity Ratios 34
Profitability Ratios 34
Cost Ratios 35
Liquidity Ratios 35
Leverage Ratios 36
Efficiency Ratios 36
List of Figures
Adventrx Pharmaceuticals, Inc., Pipeline Products by Therapy Area 8
Adventrx Pharmaceuticals, Inc., Pipeline Products by Development Phase 9
Adventrx Pharmaceuticals, Inc., Performance Chart (2007 - 2011) 23
Adventrx Pharmaceuticals, Inc., Ratio Charts 25
Adventrx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2006 to YTD 2012 26
Adventrx Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2006 to YTD 2012 27
